ACHV 5.11 Achieve Life Sciences, Inc.
| Range: | 3.03-5.98 | Vol Avg: | 120598 | Last Div: | 0 | Changes: | 0.03 |
| Beta: | 1.57 | Cap: | 0.17B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Oct 12 1995 | Empoloyees: | 22 | ||
| CUSIP: | 004468203 | CIK: | 0000949858 | ISIN: | US0044685008 | Country: | CA |
| CEO: | Dr. Richard A. B. Stewart | Website: | https://www.achievelifesciences.com | ||||
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow